August 28, 2026
Holly Hepburn
Renewed clinical interest in psychedelics has drawn attention to their challenging effects, yet most phenomenological and psychometric work derives from psilocybin, leaving cross-substance variation underexplored. This thesis employed codebook thematic analysis to examine challenging experiences across DMT, psilocybin, MDMA, and ketamine, utilising 146 naturalistic accounts collected from...
European Journal of Drug Metabolism and Pharmacokinetics
August 28, 2026
Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Psilocybin/Psilocin from Psilocybe cubensis (Magic Mushroom) in Treatment-Resistant Depression.
Nature Communications
August 27, 2026
Chenchen Song, Tinya Chang, Tobias Buchborn et al.
Psilocybin, a psychoactive compound contained in certain mushrooms, can provoke profound psychedelic experiences and also exerts established and controversial therapeutic efficacy in clinical depression and other neuropsychiatric conditions respectively. Here we report that a single systemic administration of the serotonergic psychedelic psilocybin can durably promote social behaviour in the...
Health Affairs Scholar
August 27, 2026
Danielle R Adams, Morgan Hartman, Lisa Gong et al.
Abstract Introduction Oregon is the first US state to permit supervised psilocybin services through a nonmedical, wellness-based model. We examined what prospective clients with psychiatric histories encounter when contacting service centers, including how staff communicate about safety, eligibility, and cost. Methods We conducted a mystery shopper study of 26 licensed service centers in Oregon...
bioRxiv (Cold Spring Harbor Laboratory)
August 27, 2026
Chloe L. West, Bradley Baker, Annabel Duran et al.
preprint
Abstract Background Serotonergic psychedelics show promise for treating psychiatric disorders, with symptom improvements lasting for weeks after a single dose. Clarifying the neural basis of these effects would benefit from an identification of empirical biomarkers of such lasting shifts in brain function. Resting state EEG offers a rapid (<5 minute), low-cost window into functional brain...
Psychopharmacology
August 27, 2026
Frederick S. Barrett, David Wolinsky, Zach Daily et al.
RATIONALE: Delta-9-tetrahydrocannabinol (Δ9-THC) has been reported to evoke psychedelic-like experiences at high doses in some individuals. However, the doses of Δ9-THC that occasion such effects and the phenomenology of these experiences are poorly understood. OBJECTIVES: This brief report presents preliminary findings from a pilot human laboratory study that directly compared the acute...
bioRxiv (Cold Spring Harbor Laboratory)
August 25, 2026
Roberto De Filippo, Ryan Gillis, David G Wyrick et al.
preprint
Abstract Psilocybin profoundly alters visual perception, yet the neuronal mechanisms underlying these effects remain unclear. Here we combined large-scale Neuropixels recordings with cell-type-specific optogenetics in head-fixed mice performing a visual change-detection task. Psilocybin severely impaired task performance without overt motor deficits. In cortex, the drug modestly suppressed...
Journal of Psychopharmacology
August 25, 2026
Praachi Tiwari, Bryan W. Jenkins, Catherine F Moore et al.
Psychedelics have emerged as promising pharmacological agents for treating a range of neuropsychiatric disorders. While preclinical studies have provided valuable insight into the neural mechanisms underlying their effects, systematic characterization of psychedelic effects on inherent spontaneous behaviors in animal models remains limited. In the current study, male and female Sprague-Dawley...
medRxiv
August 22, 2026
Tobias P. Whelan, Mihail Dimitrov, Lucas G. S. França et al.
preprint
Importance There is increasing interest in the potential of psilocybin to treat mental health and neurodevelopmental conditions. At high doses, the therapeutic benefit of psilocybin is linked to greater functional connectivity or integration between large-scale brain networks which underpin mood, emotion and cognition. However, it is unknown how the brain responds to psilocybin in autism - a...
Nature Medicine
August 21, 2026
The trials of translating psilocybin treatment from research to practice.